Über uns
Über uns
Führungsteam
Partnerschaften
Unsere Standorte
Technologie
Technologie
Produktion
Publikationen
Pipeline
Newsroom
News
Events
Downloads
Investor Relations
Überblick
Aktieninformation
Analysten-Coverage
Außerordentliche Hauptversammlung 2023
Finanzberichte
Corporate Governance
E-Mail Alert
Karriere
Werden Sie Teil der RNA people
Ausbildung
Aktuelle Stellenangebote
DE
RNA Immunomodulator
Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors
by Sovereign
A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects
by Sovereign
Immunological effects of a novel RNA-based adjuvant in liver cancer patients
by Sovereign
A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
by Sovereign
